vs

Side-by-side financial comparison of Lennox International (LII) and Moderna (MRNA). Click either name above to swap in a different company.

Lennox International is the larger business by last-quarter revenue ($1.2B vs $1.0B, roughly 1.2× Moderna). Lennox International runs the higher net margin — 13.6% vs -19.7%, a 33.2% gap on every dollar of revenue. On growth, Lennox International posted the faster year-over-year revenue change (-11.2% vs -45.4%). Lennox International produced more free cash flow last quarter ($376.7M vs $-880.0M). Over the past eight quarters, Lennox International's revenue compounded faster (6.8% CAGR vs -45.0%).

Lennox International Inc. is an American provider of climate control products for the heating, ventilation, and air conditioning (HVAC) and refrigeration markets. Based in Richardson, Texas, the company is 9.8% owned by John W. Norris, III, a descendant of DW Norris, who acquired the company in 1904. The company's largest production facilities are in Saltillo, Mexico, Marshalltown, Iowa, and Orangeburg, South Carolina.

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

LII vs MRNA — Head-to-Head

Bigger by revenue
LII
LII
1.2× larger
LII
$1.2B
$1.0B
MRNA
Growing faster (revenue YoY)
LII
LII
+34.3% gap
LII
-11.2%
-45.4%
MRNA
Higher net margin
LII
LII
33.2% more per $
LII
13.6%
-19.7%
MRNA
More free cash flow
LII
LII
$1.3B more FCF
LII
$376.7M
$-880.0M
MRNA
Faster 2-yr revenue CAGR
LII
LII
Annualised
LII
6.8%
-45.0%
MRNA

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
LII
LII
MRNA
MRNA
Revenue
$1.2B
$1.0B
Net Profit
$162.1M
$-200.0M
Gross Margin
34.7%
79.6%
Operating Margin
18.6%
-25.6%
Net Margin
13.6%
-19.7%
Revenue YoY
-11.2%
-45.4%
Net Profit YoY
-18.0%
-1638.5%
EPS (diluted)
$4.62
$-0.51

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LII
LII
MRNA
MRNA
Q4 25
$1.2B
Q3 25
$1.4B
$1.0B
Q2 25
$1.5B
Q1 25
$1.1B
Q4 24
$1.3B
$966.0M
Q3 24
$1.5B
$1.9B
Q2 24
$1.5B
Q1 24
$1.0B
Net Profit
LII
LII
MRNA
MRNA
Q4 25
$162.1M
Q3 25
$245.8M
$-200.0M
Q2 25
$277.6M
Q1 25
$120.3M
Q4 24
$197.7M
$-1.1B
Q3 24
$239.0M
$13.0M
Q2 24
$245.9M
Q1 24
$124.3M
Gross Margin
LII
LII
MRNA
MRNA
Q4 25
34.7%
Q3 25
32.8%
79.6%
Q2 25
34.8%
Q1 25
30.6%
Q4 24
33.9%
23.5%
Q3 24
32.6%
72.4%
Q2 24
33.6%
Q1 24
32.5%
Operating Margin
LII
LII
MRNA
MRNA
Q4 25
18.6%
Q3 25
21.7%
-25.6%
Q2 25
23.6%
Q1 25
14.5%
Q4 24
18.2%
-129.0%
Q3 24
20.2%
-3.8%
Q2 24
22.1%
Q1 24
15.9%
Net Margin
LII
LII
MRNA
MRNA
Q4 25
13.6%
Q3 25
17.2%
-19.7%
Q2 25
18.5%
Q1 25
11.2%
Q4 24
14.7%
-115.9%
Q3 24
16.0%
0.7%
Q2 24
16.9%
Q1 24
11.9%
EPS (diluted)
LII
LII
MRNA
MRNA
Q4 25
$4.62
Q3 25
$6.98
$-0.51
Q2 25
$7.82
Q1 25
$3.37
Q4 24
$5.52
$-2.91
Q3 24
$6.68
$0.03
Q2 24
$6.87
Q1 24
$3.47

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LII
LII
MRNA
MRNA
Cash + ST InvestmentsLiquidity on hand
$34.7M
$1.1B
Total DebtLower is stronger
$1.1B
Stockholders' EquityBook value
$1.2B
$9.3B
Total Assets
$4.1B
$12.1B
Debt / EquityLower = less leverage
0.98×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LII
LII
MRNA
MRNA
Q4 25
$34.7M
Q3 25
$59.2M
$1.1B
Q2 25
$55.1M
Q1 25
$222.9M
Q4 24
$422.3M
$1.9B
Q3 24
$255.7M
$1.6B
Q2 24
$57.8M
Q1 24
$57.6M
Total Debt
LII
LII
MRNA
MRNA
Q4 25
$1.1B
Q3 25
$838.2M
Q2 25
$835.7M
Q1 25
$834.2M
Q4 24
$833.1M
Q3 24
$827.6M
Q2 24
$1.1B
Q1 24
$1.2B
Stockholders' Equity
LII
LII
MRNA
MRNA
Q4 25
$1.2B
Q3 25
$1.1B
$9.3B
Q2 25
$900.5M
Q1 25
$852.5M
Q4 24
$850.2M
$10.9B
Q3 24
$754.0M
$11.9B
Q2 24
$577.4M
Q1 24
$368.8M
Total Assets
LII
LII
MRNA
MRNA
Q4 25
$4.1B
Q3 25
$3.5B
$12.1B
Q2 25
$3.7B
Q1 25
$3.5B
Q4 24
$3.5B
$14.1B
Q3 24
$3.3B
$15.8B
Q2 24
$3.2B
Q1 24
$3.0B
Debt / Equity
LII
LII
MRNA
MRNA
Q4 25
0.98×
Q3 25
0.78×
Q2 25
0.93×
Q1 25
0.98×
Q4 24
0.98×
Q3 24
1.10×
Q2 24
1.95×
Q1 24
3.13×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LII
LII
MRNA
MRNA
Operating Cash FlowLast quarter
$405.9M
$-847.0M
Free Cash FlowOCF − Capex
$376.7M
$-880.0M
FCF MarginFCF / Revenue
31.5%
-86.6%
Capex IntensityCapex / Revenue
2.4%
3.2%
Cash ConversionOCF / Net Profit
2.50×
TTM Free Cash FlowTrailing 4 quarters
$638.8M
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LII
LII
MRNA
MRNA
Q4 25
$405.9M
Q3 25
$300.7M
$-847.0M
Q2 25
$86.8M
Q1 25
$-35.8M
Q4 24
$332.4M
$825.0M
Q3 24
$452.1M
$-1.6B
Q2 24
$184.0M
Q1 24
$-22.8M
Free Cash Flow
LII
LII
MRNA
MRNA
Q4 25
$376.7M
Q3 25
$265.1M
$-880.0M
Q2 25
$58.3M
Q1 25
$-61.3M
Q4 24
$272.2M
$303.0M
Q3 24
$410.9M
$-1.7B
Q2 24
$151.3M
Q1 24
$-52.3M
FCF Margin
LII
LII
MRNA
MRNA
Q4 25
31.5%
Q3 25
18.6%
-86.6%
Q2 25
3.9%
Q1 25
-5.7%
Q4 24
20.2%
31.4%
Q3 24
27.4%
-92.2%
Q2 24
10.4%
Q1 24
-5.0%
Capex Intensity
LII
LII
MRNA
MRNA
Q4 25
2.4%
Q3 25
2.5%
3.2%
Q2 25
1.9%
Q1 25
2.4%
Q4 24
4.5%
54.0%
Q3 24
2.8%
8.1%
Q2 24
2.3%
Q1 24
2.8%
Cash Conversion
LII
LII
MRNA
MRNA
Q4 25
2.50×
Q3 25
1.22×
Q2 25
0.31×
Q1 25
-0.30×
Q4 24
1.68×
Q3 24
1.89×
-120.46×
Q2 24
0.75×
Q1 24
-0.18×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LII
LII

Residential Heating And Cooling$699.8M59%
Commercial Heating And Cooling$495.2M41%

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

Related Comparisons